N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease

BMC Medical Genetics

Volumn 7, Issue , 2006, Pages

  Borlak, Juergen ^a,b   Reamon Buettner, Stella Marie ^a  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; LEVODOPA; NAT2 PROTEIN, HUMAN;

ACETYLATION; ALLELE; ARTICLE; CAUCASIAN; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SYSTEMATIC REVIEW; VALIDATION PROCESS; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33646199441     PISSN: 14712350     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-7-30     Document Type: Article

References (24)

1. Warner TT, Schapira AH: Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003, 53(Suppl 3):S16-S23.
2. Maraganore DM, de Andrade M, Lesnick TG, Farrer MJ, Bower JH, Hardy JA, Rocca WA. Complex interactions in Parkinson's disease: a two-phased approach. Mov Disord 2003, 18:631-636.
3. Maraganore DM, Lesnick TG, Elbaz A, Chartier-Harlin MC, Gasser T, Kruger R, Hattori N, Mellick GD, Quattrone A, Satoh J, Toda T, Wang J, Ioannidis JP, de Andrade M, Rocca WA. UCHLI is a Parkinson's disease susceptibility gene. Ann Neurol 2004, 55:512-521.
4. Nagatsu T. Amine-related neurotoxins in Parkinson's disease: past, present, and future. Neurotoxicol Teratol 2002, 24:565-569.
5. Butcher NJ, Boukouvala S, Sim E, Minchin RF: Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics 2002, 2:30-42.
6. Grant DM, Goodfellow GH, Sugamori K, Durette K: Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 2000, 61(3):204-211.
7. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y: Molecular genetics and epidemiology of the NAT1 and NAT2 acertylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000, 9:29-42.
8. Agundez JA, Jimenez-Jimenez FJ, Luengo A, Molina JA, Orti-Pareja M, Vazquez A, Ramos F, Duarte J, Coria F, Ladero JM, Alvarez-Cermeno JC, Benitez J: Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease. Neurology 1998, 51:1587-1592.
9. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW: Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997, 350:1136-1139.
10. Bandmann O, Vaughan JR, Holmans P, Marsden CD, Wood NW: Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease. Mov Disord 2000, 15:30-35.
11. Bialecka M, Gawronska-Szklarz B, Drozdzik M, Honczarenko K, Stankiewicz J: N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population. Eur J Clin Pharmacol 2002, 57:857-862.
12. Chan DK, Lam MK, Wong R, Hung WT, Wilcken DE: Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese. Neurology 2003, 60:1002-1005.
13. Chaudhary S, Behari M, Dihana M, Swaminath PV, Govindappa ST, Jayaram S, Singh S, Muthane UB, Juyal RC, B K T: Association of N-acetyltransferase 2 gene polymorphism and slow acetylator phenotype with young onset and late onset Parkinson's disease among Indians. Pharmacogenet Genomics 2005, 15:731-735.
14. Dupret JM, Longuemaux S, Lucotte G: Acetylator genotype for N-acetyltransferase 2 and Parkinson's disease. Ann Neurol 1999, 46:433-434.
15. Harhangi BS, Oostra BA, Heutink P, van Duijn CM, Hofman A, Breteler MM: N-acetyltransferase-2 polymorphism in Parkinson's disease: the Rotterdam study. J Neurol Neurosurg Psychiatry 1999, 67:518-520.
16. Igbokwe E, Ogunniyi AO, Osuntokun BO: Xenobiotic metabolism in idiopathic Parkinson's disease in Nigerian Africans. East Afr Med J 1993, 70:807-809.
17. Ladero JM, Jimenez FJ, Benitez J, Fernandez-Gundin MJ, Martinez C, Llerena A, Cobaleda J, Munoz JJ: Acetylator polymorphism in Parkinson's disease. Eur J Clin Pharmacol 1989, 37:391-393.
18. Maraganore DM, Farrer MJ, Hardy JA, McDonnell SK, Schaid DJ, Rocca WA: Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease. Mov Disord 2000, 15:714-719.
19. Nicholl DJ, Bennett P, Hiller L, Bonifati V, Vanacore N, Fabbrini G, Marconi R, Colosimo C, Lamberti P, Stocchi F, Bonuccelli U, Vieregge P, Ramsden DB, Meco G, Williams AC: A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 1999, 53:1415-1421.
20. van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Roses AD, Stajich JM, Booze MW, Fujiwara K, Gibson RA, Middleton LT, Scott BL, Pericak-Vance MA, Vance JM: Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology 2003, 60:1189-1191.
21. Grundmann M, Earl CD, Sautter J, Henze C, Oertel WH, Bandmann O: Slow N-acetyltransferase 2 status leads to enhanced intrastriatal dopamine depletion in 6-hydroxydopaminelesioned rats. Exp Neurol 2004, 187:199-202.
22. Cascorbi I, Drakoulis N, Brockmoller J, Maurer & Sperling K, Roots I: Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995, 57:581-592.
23. The R Project for Statistical [http://www.r-project.org].
24. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T: Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000, 55(4):533-538.